The role of intraprostatic inflammation in the acute urinary retention

International Journal of Preventive Medicine

Volumn 2, Issue 1, 2011, Pages 28-31

  Asgari, Seyed Alaeddin ^a   Mohammadi, Mohaddeseh ^a  

^a GUILAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Acute urinary retention; Benign prostatic hyperplasia; Inflammation

Indexed keywords

AGED; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INCIDENCE; INFLAMMATION; INTRAPROSTATIC INFLAMMATION; IRAN; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; ORGAN WEIGHT; PROSTATE HYPERTROPHY; PROSTATE WEIGHT; PROSTATECTOMY; TRANSURETHRAL RESECTION; URINARY TRACT OBSTRUCTION; URINE RETENTION;

EID: 79952057868     PISSN: 20087802     EISSN: 20088213     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Mishra VC, Allen DJ, Nicolaou C, Sharif H, Hudd C, Karim OM, et al. Does intraprostatic inflammation have a role in the pathogenesis and progression of benign prostatic hyperplasia? BJU Int 2007; 100(2): 327-31.
2. St Sauver JL, Jacobson DJ, McGree ME, Lieber MM, Jacobsen SJ. Protective association between nonsteroidal antiinflammatory drug use and measures of benign prostatic hyperplasia. Am J Epidemiol 2006; 164(8): 760-8.
3. Verhamme KM, Dieleman JP, Bleumink GS, van der Lei J, Sturkenboom MC, Artibani W, et al. Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care; the Triumph project. Eur Urol 2002; 42(4): 323-8.
4. Verhamme KM, Dieleman JP, Bleumink GS, Bosch JL, Stricker BH, Sturkenboom MC. Treatment strategies, patterns of drug use and treatment discontinuation in men with LUTS suggestive of benign prostatic hyperplasia: the Triumph project. Eur Urol 2003; 44(5): 539-45.
5. Nickel JC. The overlapping lower urinary tract symptoms of benign prostatic hyperplasia and prostatitis. Curr Opin Urol 2006; 16(1): 5-10.
6. Safarinejad MR. Prevalence of benign prostatic hyperplasia in a population-based study in Iranian men 40 years old or older. Int Urol Nephrol 2008; 40(4): 921-31.
7. Nickel JC. Prostatic inflammation in benign prostatic hyperplasia; the third component? Can J Urol 1994; 1(1): 1-4.
8. Nickel JC, Downey J, Young I, Boag S. Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int 1999; 84(9): 976-81.
9. Chronic Prostatitis Workshop. Proceedings of the National Institute of Diabetes and Digestive and Kidney Diseases; 1995 Dec 7- 8; Maryland; USA.
10. Di Silverio F, Gentile V, De Matteis A, Mariotti G, Giuseppe V, Luigi PA, et al. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol 2003; 43(2): 164-75.
11. Kohnen PW, Drach GW. Patterns of inflammation in prostatic hyperplasia: a histologic and bacteriologic study. J Urol 1979; 121(6): 755-60.
12. Roehrborn CG, Kaplan SA, Noble WD, Slawin KM, McVary KT, Kusek JW. The impact of acute or chronic inflammation in baseline biopsy on the risk of clinical progression of BPH. Results from the MTOPS study. J Urol 2005; 173(Suppl abstract): 1277.
13. Emberton M, Elhilali M, Matzkin H, Harving N, van Moorselaar J, Hartung R, et al. Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily. Urology 2005; 66(2): 316-22.
14. Stoner E. The clinical development of a 5 alphareductase inhibitor, finasteride. J Steroid Biochem Mol Biol 1990; 37(3): 375-8.
15. Oesterling JE. LHRH agonists. A nonsurgical treatment for benign prostatic hyperplasia. J Androl 1991; 12(6): 381-8.
16. McConnell JD, Roehrborn CG, Bautista OM, Andriole Jr. GL, Dixon CM, Kusek JW, et al. The longterm effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349(25): 2387-98.
17. Moore RA. Inflammation of the prostate gland. J Urol 1937; 38: 173-82.
18. McNeal JE. Regional morphology and pathology of the prostate. Am J Clin Pathol 1968; 49(3): 347-57.
19. Maksem JA, Johenning PW, Galang CF. Prostatitis and aspiration biopsy cytology of prostate. Urology 1988; 32(3): 263-8.
20. Theyer G, Kramer G, Assmann I, Sherwood E, Preinfalk W, Marberger M, et al. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest 1992; 66(1): 96-107.
21. Steiner G, Gessl A, Kramer G, Schollhammer A, Forster O, Marberger M. Phenotype and function of peripheral and prostatic lymphocytes in patients with benign prostatic hyperplasia. J Urol 1994; 151(2): 480-4.
22. Zha S, Yegnasubramanian V, Nelson WG, Isaacs WB, De Marzo AM. Cyclooxygenases in cancer: progress and perspective. Cancer Lett 2004; 215(1): 1-20.
23. Falahatkar S, Mokhtari G, Pourreza F, Asgari SA, Kamran AN. Celecoxib for treatment of nocturia caused by benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled study. Urology 2008; 72(4): 813-6.